Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's drug regulator Pharmaceuticals and Medical Devices Agency has opened its doors in the last three years to preapproval discussions with drug companies. While the move has helped somewhat to ease the agency's drug approval lag, it can also pay benefits to companies applying for approvals in neighboring Asian countries
You may also be interested in...
Demand For Insight Grows As Firms Look To Asia CROs For More Than Service Work – Singapore Conference
Although failing fast, early and cheaply to avoid costly late-stage trials is a priority for companies that outsource early trials to Asia, companies are increasingly looking for CROs that take initiative and offer more than just service work.
Japan's PMDA Considering Data Monitoring Committee Guidance, Weighs In On Adaptive Design - DIA Japan
TOKYO - Drug reviewers in Japan do not see as many adaptive trial designs as reviewers in the U.S., and to ensure data integrity for the potentially controversial trials companies should consult with the Pharmaceuticals and Medical Devices Agency as early as possible, an official said, while adding that regulatory guidance may soon be on the way
Japan's PMDA Considering Data Monitoring Committee Guidance, Weighs In On Adaptive Design - DIA Japan
TOKYO - Drug reviewers in Japan do not see as many adaptive trial designs as reviewers in the U.S., and to ensure data integrity for the potentially controversial trials companies should consult with the Pharmaceuticals and Medical Devices Agency as early as possible, an official said, while adding that regulatory guidance may soon be on the way